Foghorn Therapeutics Inc. (FHTX)
$1.85-5.13%Close
SELLCRISIS · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $109M
- Beta
- 3.01
- P/E (TTM)
- -1.87
- Short % float
- 7.85%
- Days to cover
- 4.3
- SI change
- +8.0%
- 1W
- -6.09%
- 1M
- -57.57%
- vs SPY 1W
- -5.95%
- vs SPY 1M
- -60.07%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 8
- GROWTH
- 28
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC43.6%
REV YoY-
ROE72.6%
EPS YoY-
ROA-31.8%
GROSS43
OP-186
NET-176
[VALUATION]
P/E TTM-1.87
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-1.61
P/FCF-
EV/EBITDA-1.34
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO3.36
ND/EBITDA-
BETA3.01
Company news
FAQ
- What is LOPJLB’s current signal on FHTX?
- LOPJLB’s latest quantitative signal on Foghorn Therapeutics Inc. (FHTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is FHTX in?
- Foghorn Therapeutics Inc. (FHTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Foghorn Therapeutics Inc. (FHTX) do?
- Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex syst…